BACKGROUND: The baseline absolute monocyte count and absolute lymphocyte count were used to generate a prognostic index (the AMLPI) for survival in diffuse large B-cell lymphoma (DLBCL). METHODS: Data from 245 patients with DLBCL who were treated with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) were reviewed. By using the values previously reported for the AMLPI, its prognostic value was examined in our population. RESULTS: After a median follow-up of 22 months for censored observations, the 3-year progression-free survival (PFS) rates for the international prognostic index (IPI) 0-2 and 3-5 risk groups were 73% and 58%, respectively (P = .0004); comparable overall survival (OS) rates were 88% and 68%, respectively (P < .0001). For patients with IPI scores of 0-2, 1-year PFS rates for AMLPI low-, intermediate-, and high-risk groups were 92%, 89%, and 80%, respectively (P = .022); comparable 1-year OS rates were 96%, 95%, and 80%, respectively (P = .049). By multivariate analysis, with the adjustment of IPI in the model, AMLPI effects (low- vs. high-risk groups) on PFS and OS rates were significant, with P = .046 (hazard ratio [HR] 0.402 [95% CI, 0.164-0.986] and P = .052 (HR 0.325 [95% CI, 0.104-1.011]), respectively. CONCLUSIONS: The absolute monocyte and lymphocyte counts prognostic index (the AMLPI) may add prognostic value beyond that of the IPI for patients with DLBCL who receive R-CHOP.
BACKGROUND: The baseline absolute monocyte count and absolute lymphocyte count were used to generate a prognostic index (the AMLPI) for survival in diffuse large B-cell lymphoma (DLBCL). METHODS: Data from 245 patients with DLBCL who were treated with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) were reviewed. By using the values previously reported for the AMLPI, its prognostic value was examined in our population. RESULTS: After a median follow-up of 22 months for censored observations, the 3-year progression-free survival (PFS) rates for the international prognostic index (IPI) 0-2 and 3-5 risk groups were 73% and 58%, respectively (P = .0004); comparable overall survival (OS) rates were 88% and 68%, respectively (P < .0001). For patients with IPI scores of 0-2, 1-year PFS rates for AMLPI low-, intermediate-, and high-risk groups were 92%, 89%, and 80%, respectively (P = .022); comparable 1-year OS rates were 96%, 95%, and 80%, respectively (P = .049). By multivariate analysis, with the adjustment of IPI in the model, AMLPI effects (low- vs. high-risk groups) on PFS and OS rates were significant, with P = .046 (hazard ratio [HR] 0.402 [95% CI, 0.164-0.986] and P = .052 (HR 0.325 [95% CI, 0.104-1.011]), respectively. CONCLUSIONS: The absolute monocyte and lymphocyte counts prognostic index (the AMLPI) may add prognostic value beyond that of the IPI for patients with DLBCL who receive R-CHOP.
Authors: Ryan A Wilcox; Andrew L Feldman; David A Wada; Zhi-Zhang Yang; Nneka I Comfere; Haidong Dong; Eugene D Kwon; Anne J Novak; Svetomir N Markovic; Mark R Pittelkow; Thomas E Witzig; Stephen M Ansell Journal: Blood Date: 2009-07-13 Impact factor: 22.113
Authors: Nicolas Mounier; Josette Briere; Christian Gisselbrecht; Jean-Francois Emile; Pierre Lederlin; Catherine Sebban; Francoise Berger; Andre Bosly; Pierre Morel; Herve Tilly; Reda Bouabdallah; Felix Reyes; Philippe Gaulard; Bertrand Coiffier Journal: Blood Date: 2003-02-06 Impact factor: 22.113
Authors: Ryan A Wilcox; David A Wada; Steven C Ziesmer; Sherine F Elsawa; Nneka I Comfere; Allan B Dietz; Anne J Novak; Thomas E Witzig; Andrew L Feldman; Mark R Pittelkow; Stephen M Ansell Journal: Blood Date: 2009-08-11 Impact factor: 22.113
Authors: G Lenz; G Wright; S S Dave; W Xiao; J Powell; H Zhao; W Xu; B Tan; N Goldschmidt; J Iqbal; J Vose; M Bast; K Fu; D D Weisenburger; T C Greiner; J O Armitage; A Kyle; L May; R D Gascoyne; J M Connors; G Troen; H Holte; S Kvaloy; D Dierickx; G Verhoef; J Delabie; E B Smeland; P Jares; A Martinez; A Lopez-Guillermo; E Montserrat; E Campo; R M Braziel; T P Miller; L M Rimsza; J R Cook; B Pohlman; J Sweetenham; R R Tubbs; R I Fisher; E Hartmann; A Rosenwald; G Ott; H-K Muller-Hermelink; D Wrench; T A Lister; E S Jaffe; W H Wilson; W C Chan; L M Staudt Journal: N Engl J Med Date: 2008-11-27 Impact factor: 91.245
Authors: Wan Kyu Eo; Da Wun Jeong; Hye Jung Chang; Kyu Yeoun Won; Sung Il Choi; Se Hyun Kim; Sung Wook Chun; Young Lim Oh; Tae Hwa Lee; Young Ok Kim; Ki Hyung Kim; Yong Il Ji; Ari Kim; Heung Yeol Kim Journal: World J Gastroenterol Date: 2015-03-07 Impact factor: 5.742
Authors: M Stotz; M Pichler; G Absenger; J Szkandera; F Arminger; R Schaberl-Moser; H Samonigg; T Stojakovic; A Gerger Journal: Br J Cancer Date: 2013-12-19 Impact factor: 7.640
Authors: Y Kusano; M Yokoyama; Y Terui; N Nishimura; Y Mishima; K Ueda; N Tsuyama; H Yamauchi; A Takahashi; N Inoue; K Takeuchi; K Hatake Journal: Blood Cancer J Date: 2017-04-21 Impact factor: 11.037